Advertisement VaxInnate completes patient enrollment in VAX2012Q Phase I influenza vaccine trial - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

VaxInnate completes patient enrollment in VAX2012Q Phase I influenza vaccine trial

US-based biotechnology firm VaxInnate completed patient enrollment in the Phase I trial of its experimental recombinant quadrivalent seasonal influenza vaccine, VAX2012Q.

Around 316 healthy adults aged 18-40 were enrolled in the Phase I trial and they were each evaluated for vaccine tolerability and immune response at 21 days post-vaccination.

These patients will be monitored for one year following their vaccination to evaluate long-term safety.

The top-line results have showed that doses as low as 2mcg per component were immunogenic, with mean seroprotection rates exceeding 90% for each of the four vaccine components at the day 21.

In the trial, VAX2012Q was generally well tolerated and the most commonly reported adverse event was mild to moderate arm pain.

VaxInnate vice-president of research and development Dr Lynda Tussey said: "VAX2012Q continues to show great promise as a seasonal influenza vaccine in adults.

"Based on these top-line results, and pending the completion of our planned Phase Ib/II study in elderly individuals that will begin later this month, we expect to advance VAX2012Q into a Phase II study in healthy adults 18 years of age and older in 2015.

"This next stage of clinical development will confirm the VAX2012Q dose in adult and elderly individuals, and will support further development and pursuit of licensure."